Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
featured
EMERALD – Breast Cancer

People with breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.  

cancer
  • 54 views
  • 23 Nov, 2020
  • 1 location
featured
HER2 Negative Advanced Breast Cancer

People with HER2 negative advanced breast cancer are asked to participate in a research study being conducted by Queens Hospital Center.  

advanced breast cancer
HER2
cancer
  • 27 views
  • 28 Oct, 2019
  • 1 location
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer

urine test
measurable disease
tamoxifen
HER2
ct scan
  • 6 views
  • 09 Dec, 2020
  • 27 locations
A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

-positive unresectable locally advanced or metastatic triple-negative adenocarcinoma of the breast (TNBC) who have not received prior systemic cytotoxic therapy for unresectable locally advanced or

HER2
pd-l1
programmed cell death 1 ligand 1
adenocarcinoma
metastasis
  • 146 views
  • 17 Jan, 2021
  • 159 locations
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, …

ejection fraction
estrogen receptor
pet/ct scan
isolation procedure
metastasis
  • 814 views
  • 24 Jan, 2021
  • 811 locations
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor …

pertuzumab
HER2
ejection fraction
estrogen receptor
adenocarcinoma
  • 438 views
  • 17 Jan, 2021
  • 416 locations
A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

  • 370 views
  • 14 Jan, 2021
  • 33 locations
An Efficacy Study of the Xoft Axxent eBx IORT System "Lite"

The purpose of this trial is to assess the efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. A comparison will be made to the current standard of care, whole breast irradiation (WBI), in women with early stage breast cancer.

ductal carcinoma in situ
breast cancer
breast cancer staging
ductal carcinoma
carcinoma in situ
  • 0 views
  • 23 Dec, 2020
  • 1 location
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to 13 % with radiotherapy. Half of the recurrences …

HER2
estrogen receptor
ki-67
breast-conserving surgery
re-excision
  • 15 views
  • 25 Jan, 2021
  • 13 locations
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with aromatase-inhibitors. Nonetheless, a considerable amount of patients suffer a relapse of their cancer while on treatment with tamoxifen. Tamoxifen …

tamoxifen
ductal carcinoma in situ
cancer treatment
neutrophil count
body mass index
  • 0 views
  • 25 Jan, 2021
  • 40 locations